News Releases

 

BioSante Pharmaceuticals Common Stock Approved for Listing on NASDAQ Global Market

Lincolnshire, Illinois (November 1, 2007) – BioSante Pharmaceuticals, Inc. (Amex: BPA) today announced that Stephen M. Simes, the company’s president and chief executive officer, will present a BioSante corporate and clinical overview at the Acumen BioFin Rodman and Renshaw Annual Healthcare Conference, taking place at the New York Palace Hotel in New York City, from November 5 to 7, 2007. Mr. Simes will present on November 5, 2007 at 4:05 p.m. local time.

A live audio webcast of BioSante’s presentation may be accessed and a replay will be available at the same link for 90 days.

Rodman & Renshaw, a full-service investment bank, is a leading investment banking firm to the biotechnology and pharmaceutical sectors. This conference will feature presentations from over 350 small and medium biotechnology and pharmaceutical companies, to an audience comprised of stock research analysts, institutional money managers, brokers and individual investors, as well as biotechnology and pharmaceutical industry representatives.

About BioSante Pharmaceuticals, Inc.

BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante’s lead products include Elestrin™ (estradiol gel) developed through U.S. Food and Drug Administration (FDA) approval by BioSante indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S.by Bradley Pharmaceuticals, Inc., BioSante’s licensee, and LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante for the treatment of female sexual dysfunction (FSD).

Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, drug delivery, and aesthetic medicine. Additional information is available online at: www.biosantepharma.com.

###

For more information please contact:

For Media:
Harris D. McKinney, Inc.
Alan Zachary
(312) 506-5220
azachary@harrisdmckinney.com